Table 1 Open in new tab Demographics and...

Table 1

Demographics and disease characteristics at True North baseline of patients who entered the OLE in clinical response.

Characteristic	Week 52 clinical responders^a [n = 131]
Age, y, mean [SD]	44.3 [13.6]
Female, n [%]	68 [51.9]
Body mass index, kg/m², mean [SD]	25.9 [5.8]
Age at UC diagnosis, y, mean [SD]	36.1 [13.4]
Years since UC diagnosis, mean [SD]	8.5 [7.3]
Extent of UC disease, n [%]
Left-sided	89 [67.9]
Extensive	42 [32.1]
Corticosteroid use at screening, n [%]	31 [23.7]
Prior therapies, n [%]
5-ASA	129 [98.5]
Corticosteroid	90 [68.7]
Immunomodulator	46 [35.1]
Any biologic^b	46 [35.1]
TNF inhibitor	42 [32.1]
Non-TNF inhibitor biologic	26 [19.8]

Characteristic	Week 52 clinical responders^a [n = 131]
Age, y, mean [SD]	44.3 [13.6]
Female, n [%]	68 [51.9]
Body mass index, kg/m², mean [SD]	25.9 [5.8]
Age at UC diagnosis, y, mean [SD]	36.1 [13.4]
Years since UC diagnosis, mean [SD]	8.5 [7.3]
Extent of UC disease, n [%]
Left-sided	89 [67.9]
Extensive	42 [32.1]
Corticosteroid use at screening, n [%]	31 [23.7]
Prior therapies, n [%]
5-ASA	129 [98.5]
Corticosteroid	90 [68.7]
Immunomodulator	46 [35.1]
Any biologic^b	46 [35.1]
TNF inhibitor	42 [32.1]
Non-TNF inhibitor biologic	26 [19.8]

5-ASA, 5-aminosalicylate; OLE, open-label extension; RBS, rectal bleeding subscore; SFS, stool frequency subscore; TNF, tumour necrosis factor; UC, ulcerative colitis.

^aClinical response is defined as a reduction from baseline in the 3-component Mayo score [sum of RBS, SFS, and endoscopy subscore] of ≥2 points and ≥35% and reduction from baseline in the RBS of ≥1 point or an absolute RBS of ≤1 point.

^bExcluding three patients exposed to only Janus kinase inhibitors.

This Feature Is Available To Subscribers Only